Cuong V. Do
CIK: 0001477037
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Aug 27, 2026BIVI
BIOVIE INC.
Purchase(P)Direct15.2K shares at avg. $2.08$32K - Aug 14, 2026ADAG
Adagene Inc.
Purchase(P)Direct2K shares at avg. $3.75$8K - Aug 13, 2026ADAG
Adagene Inc.
Award(A)DirectNonqualified Stock Option (Right to Buy)
20K shares- - Jan 5, 2026BIVI
BIOVIE INC.
Award(A)IndirectStock Option (right to buy)
665.3K shares- - Aug 7, 2025BIVI
BIOVIE INC.
Purchase(P)Indirect5K shares- - Dec 20, 2024BIVI
BIOVIE INC.
Award(A)IndirectStock Option (right to buy)
104.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 27, 2026 |  BIVI BIOVIE INC. | Purchase(P) | 15,210 | $2.08 | $31,637 | Direct |
| Aug 14, 2026 |  ADAG Adagene Inc. | Purchase(P) | 2,000 | $3.75 | $7,500 | Direct |
| Aug 13, 2026 | ADAG Adagene Inc. | Award(A) Nonqualified Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Jan 5, 2026 | BIVI BIOVIE INC. | Award(A) Stock Option (right to buy) | 665,300 | - | - | Indirect |
| Aug 7, 2025 | BIVI BIOVIE INC. | Purchase(P) | 5,000 | - | - | Indirect |
| Dec 20, 2024 | BIVI BIOVIE INC. | Award(A) Stock Option (right to buy) | 104,502 | - | - | Indirect |
1-6 of 6 transactions
About DO CUONG V
DO CUONG V (SEC CIK 0001477037) files insider reports with the SEC as President & CEO of BIOVIE INC. (BIVI) and Director of Adagene Inc. (ADAG).
Signal8 holds 7 ownership filings by DO CUONG V (1 Form 3, 6 Form 4), filed between Jan 7, 2025 and Aug 28, 2026. Those filings report 6 transactions, from Dec 20, 2024 to Aug 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DO CUONG V's filings is in SUZHOU JIANGSU.
Recent filings by DO CUONG V
- Aug 27, 2026: Open-market purchase of BIVI shares (Form 4, code P).
- Aug 14, 2026: Open-market purchase of ADAG shares (Form 4, code P).
- Aug 13, 2026: Grant or award of ADAG derivative securities (Form 4, code A).
- Jan 5, 2026: Grant or award of BIVI derivative securities (Form 4, code A).
- Aug 7, 2025: Open-market purchase of BIVI shares (Form 4, code P).
Other insiders filing for BIOVIE INC. (BIVI)
- Palumbo Joseph M, Chief Medical Officer
- Chappell Amy Suzon, Director
- KIM JOANNE WENDY, Chief Financial Officer
- ROGICH SIGMUND, Director
- Sherman Michael Edward, Director
- Farag Kameel D., Director